前收市價 | 21.99 |
開市 | 13.92 |
買盤 | 9.00 |
賣出價 | 18.40 |
拍板 | 280.00 |
到期日 | 2024-05-17 |
今日波幅 | 13.92 - 13.92 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 14 |
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript May 7, 2024 Bio-Rad Laboratories, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon everyone, and welcome to today’s Bio-Rad First Quarter 2024 Earnings Results Conference Call. At this […]
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?